Patents by Inventor Bart De Strooper
Bart De Strooper has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11346848Abstract: The present invention relates to the field of neurodegenerative diseases. More specifically, the present invention relates to a screening assay to produce compounds stabilizing the gamma-secretase enzyme substrate complex, thereby increasing gamma-secretase processivity while attenuating the release of longer A? peptides. More specifically, gamma-secretase stabilizing compounds increase thermostability of the enzyme/substrate complexes acting in the sequential ?-secretase processing of APP, to result in reduced amyloidogenic A? production, thereby preventing Alzheimer disease.Type: GrantFiled: January 10, 2018Date of Patent: May 31, 2022Assignees: VIB VZW, Katholieke Universiteit Leuven, KU Leuven R&DInventors: Bart De Strooper, Lucia Chávez Gutiérrez, Maria Szaruga
-
Patent number: 10829528Abstract: The present invention relates to the field of disorders of the central nervous system, in particular neurological and psychiatric disorders, and the prevention and/or treatment thereof. In particular, the present invention relates to the finding that soluble amyloid precursor protein a (sAPP?) presents a particular binding site, which allows for binding to the GABABR1a receptor, thereby causing an agonistic effect through specific binding to Sushi domain 1 of GABABR1a. As a result, the frequencies of excitatory and inhibitory postsynaptic currents are reduced. Accordingly, the invention provides compounds able to interfere with the association of sAPP? with Sushi domain 1 of GABABR1a and as such with selective impairment of GABABR1sa beneficial in neurological and psychiatric disorders. The invention as well provides methods and (high content) screening assays for the production of said compounds.Type: GrantFiled: July 14, 2017Date of Patent: November 10, 2020Assignees: VIB VZW, Katholieke Universiteit Leuven, K.U.Leuven R&DInventors: Joris De Wit, Heather Rice, Bart De Strooper
-
Publication number: 20190339292Abstract: The present invention relates to the field of neurodegenerative diseases. More specifically, the present invention relates to a screening assay to produce compounds stabilizing the gamma-secretase enzyme substrate complex, thereby increasing gamma-secretase processivity while attenuating the release of longer A? peptides. More specifically, gamma-secretase stabilizing compounds increase thermostability of the enzyme/substrate complexes acting in the sequential ?-secretase processing of APP, to result in reduced amyloidogenic A? production, thereby preventing Alzheimer disease.Type: ApplicationFiled: January 10, 2018Publication date: November 7, 2019Inventors: Bart DE STROOPER, Lucia CHÁVEZ GUTIÉRREZ, Maria SZARUGA
-
Patent number: 10377834Abstract: Described are single domain antibodies with a specificity for BACE1. More specifically, described are single variable-domain antibodies derived from camelids that bind to BACE1 and are capable of inhibiting the activity of BACE1. The antibodies can be used for research and medical applications. Specific applications include the use of BACE1-specific antibodies for the treatment of Alzheimer's disease.Type: GrantFiled: January 16, 2018Date of Patent: August 13, 2019Assignees: VIB VZW, KATHOLIEKE UNIVERSITEIT LEUVEN. K.U. LEUVEN R&D, VRIJE UNIVERSITEIT BRUSSELInventors: Bart De Strooper, Els Marjaux, Lujia Zhou, Serge Muyldermans
-
Publication number: 20190225662Abstract: The present invention relates to the field of disorders of the central nervous system, in particular neurological and psychiatric disorders, and the prevention and/or treatment thereof. In particular, the present invention relates to the finding that soluble amyloid precursor protein ? (sAPP?) presents a particular binding site, which allows for binding to the GABABR1a receptor, thereby causing an agonistic effect through specific binding to Sushi domain 1 of GABABR1a. As a result, the frequencies of excitatory and inhibitory postsynaptic currents are reduced. Accordingly, the invention provides compounds able to interfere with the association of sAPP? with Sushi domain 1 of GABABR1a and as such with selective impairment of GABABR1a beneficial in neurological and psychiatric disorders. The invention as well provides methods and (high content) screening assays for the production of said compounds.Type: ApplicationFiled: July 14, 2017Publication date: July 25, 2019Applicants: VIB VZW, Katholieke Universiteit Leuven, K.U.Leuven R&DInventors: Joris DE WIT, Heather RICE, Bart DE STROOPER
-
Publication number: 20180230232Abstract: Described are single domain antibodies with a specificity for BACE1. More specifically, described are single variable-domain antibodies derived from camelids that bind to BACE1 and are capable of inhibiting the activity of BACE1. The antibodies can be used for research and medical applications. Specific applications include the use of BACE1-specific antibodies for the treatment of Alzheimer's disease.Type: ApplicationFiled: January 16, 2018Publication date: August 16, 2018Inventors: Bart De Strooper, Els Marjaux, Lujia Zhou, Serge Muyldermans
-
Patent number: 9908943Abstract: Described are single domain antibodies with a specificity for BACE1. More specifically, described are single variable-domain antibodies derived from camelids that bind to BACE1 and are capable of inhibiting the activity of BACE1. The antibodies can be used for research and medical applications. Specific applications include the use of BACE1-specific antibodies for the treatment of Alzheimer's disease.Type: GrantFiled: September 11, 2013Date of Patent: March 6, 2018Assignees: VIB VZW, KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D, VRIJE UNIVERSITEIT BRUSSELInventors: Bart De Strooper, Els Marjaux, Lujia Zhou, Serge Muyldermans
-
Patent number: 9879233Abstract: The present application relates to the field of Parkinson's disease (PD), particularly sporadic PD or PD associated with mutations in the mitochondrial kinase PINK1. A new substrate for this kinase, NdufA10, is identified herein. In Parkinson's disease, this protein is dephosphorylated, which is linked to a loss of mitochondrial membrane potential. It is shown that restoring or mimicking phosphorylation of NdufA10 restores the phenotypic defects associated with Parkinson's disease and is thus a new therapeutic paradigm.Type: GrantFiled: November 7, 2013Date of Patent: January 30, 2018Assignees: VIB VZW, KATHOLIEKE UNIVERSITEIT LEUVENInventors: Bart De Strooper, Patrik Verstreken, Vanessa Morais Epifânio
-
Publication number: 20160237166Abstract: Described are single domain antibodies with a specificity for BACE1. More specifically, described are single variable-domain antibodies derived from camelids that bind to BACE1 and are capable of inhibiting the activity of BACE1. The antibodies can be used for research and medical applications. Specific applications include the use of BACE1-specific antibodies for the treatment of Alzheimer's disease.Type: ApplicationFiled: September 11, 2013Publication date: August 18, 2016Applicants: VIB VZW, VRIJE UNIVERSITEIT BRUSSEL, KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&DInventors: Bart De Strooper, Els Marjaux, Lujia Zhou, Serge Muyldermans
-
Publication number: 20150299672Abstract: The present application relates to the field of Parkinson's disease (PD), particularly sporadic PD or PD associated with mutations in the mitochondrial kinase PINK1. A new substrate for this kinase, NdufA10, is identified herein. In Parkinson's disease, this protein is dephosphorylated, which is linked to a loss of mitochondrial membrane potential. It is shown that restoring or mimicking phosphorylation of NdufA10 restores the phenotypic defects associated with Parkinson's disease and is thus a new therapeutic paradigm.Type: ApplicationFiled: November 7, 2013Publication date: October 22, 2015Applicants: KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D, VIB VZWInventors: Bart DE STROOPER, Patrik VERSTREKEN, Vanessa MORAIS EPIFÂNIO
-
Publication number: 20150301068Abstract: The disclosure provides an extracellular target for Alzheimer's disease selected from the tetraspanin web family. The disclosure also provides diagnostic methods for the use as a target for detection of Alzheimer's disease in a subject. In addition, screening methods are provided for selecting compounds that bind or down-regulate the expression of the target.Type: ApplicationFiled: January 29, 2013Publication date: October 22, 2015Inventors: Bart DE STROOPER, Francesc GUIX
-
Publication number: 20150071940Abstract: Described are single domain antibodies with a specificity for BACE1. More specifically, described are single variable-domain antibodies derived from camelids that bind to BACE1 and are capable of inhibiting the activity of BACE1. The antibodies can be used for research and medical applications. Specific applications include the use of BACE1-specific antibodies for the treatment of Alzheimer's disease.Type: ApplicationFiled: September 11, 2013Publication date: March 12, 2015Applicants: VIB VZW, VRIJE UNIVERSITEIT BRUSSEL, KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&DInventors: Bart De Strooper, Els Marjaux, Lujia Zhou, Serge Muyldermans
-
Patent number: 8956614Abstract: The present invention relates to antibodies with a specificity for BACE1. More specifically, the invention provides monoclonal antibodies that bind to BACE1 and are capable of inhibiting the activity of BACE1 and methods producing these antibodies. The antibodies can be used for research and medical applications. Specific applications include the use of BACE1-specific antibodies for the treatment of Alzheimer's disease.Type: GrantFiled: June 15, 2010Date of Patent: February 17, 2015Assignees: VIB VZW, Katholieke Universiteit Leuven, K.U.Leuven R&DInventors: Bart De Strooper, Lujia Zhou, Wim Annaert
-
Patent number: 8790887Abstract: The invention relates to the field of disorders of the peripheral or central nervous system, in particular, Alzheimer's disease, and the prevention and/or treatment thereof. In particular, the invention relates to ARF6 and/or ARF6 effector proteins as new targets in Alzheimer's disease, and based thereon, screening methods for compounds that reduce amyloid beta peptide formation in mammalian cells by affecting ARF6-mediated endosomal sorting.Type: GrantFiled: December 6, 2010Date of Patent: July 29, 2014Assignees: VIB VZW, Katholieke Universiteit Leuven, K.U. Leuven R&DInventors: Wim Annaert, Ragna Sannerud, Katrijn Coen, Bart De Strooper
-
Patent number: 8580493Abstract: The invention relates to the field of disorders of the peripheral or central nervous system, in particular, Alzheimer's disease, and the prevention and/or treatment thereof. In particular, the invention relates to the screening of compounds that modulate GPR3 activity and/or beta-arrestin signaling in a mammalian cell and, in particular, compounds that reduce the formation of amyloid beta peptides. The invention also relates to inhibiting agents targeting beta-arrestin signaling and pharmaceutical compositions thereof, and their use in therapeutic applications of those disorders.Type: GrantFiled: June 4, 2010Date of Patent: November 12, 2013Assignees: VIB VZW, Katholieke Universiteit Leuven, K.U. Leuven R&DInventors: Bart De Strooper, Amantha Thathiah
-
Patent number: 8568717Abstract: Described are single domain antibodies with a specificity for BACE1. More specifically, described are single variable-domain antibodies derived from camelids that bind to BACE1 and are capable of inhibiting the activity of BACE1. The antibodies can be used for research and medical applications. Specific applications include the use of BACE1-specific antibodies for the treatment of Alzheimer's disease.Type: GrantFiled: April 3, 2009Date of Patent: October 29, 2013Assignees: VIB VZW, Katholieke Universiteit Leuven, K.U. Leuven R&D, Vrije Universiteit BrusselInventors: Bart De Strooper, Els Marjaux, Lujia Zhou, Serge Muyldermans
-
Publication number: 20120276076Abstract: The invention relates to the field of disorders of the peripheral or central nervous system, in particular, Alzheimer's disease, and the prevention and/or treatment thereof. In particular, the invention relates to ARF6 and/or ARF6 effector proteins as new targets in Alzheimer's disease, and based thereon, screening methods for compounds that reduce amyloid beta peptide formation in mammalian cells by affecting ARF6-mediated endosomal sorting.Type: ApplicationFiled: December 6, 2010Publication date: November 1, 2012Applicants: KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D, VIB VZWInventors: Wim Annaert, Ragna Sannerud, Katrijn Coen, Bart De Strooper
-
Publication number: 20120237526Abstract: The present invention relates to antibodies with a specificity for BACE1. More specifically, the invention provides monoclonal antibodies that bind to BACE1 and are capable of inhibiting the activity of BACE1 and methods producing these antibodies. The antibodies can be used for research and medical applications. Specific applications include the use of BACE1-specific antibodies for the treatment of Alzheimer's disease.Type: ApplicationFiled: June 15, 2010Publication date: September 20, 2012Applicants: VIB VZW, KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&DInventors: Bart De Strooper, Lujia Zhou, Wim Annaert
-
Publication number: 20120136045Abstract: The invention relates to the field of disorders of the peripheral or central nervous system, in particular, Alzheimer's disease, and the prevention and/or treatment thereof. In particular, the invention relates to the screening of compounds that modulate GPR3 activity and/or beta-arrestin signaling in a mammalian cell and, in particular, compounds that reduce the formation of amyloid beta peptides. The invention also relates to inhibiting agents targeting beta-arrestin signaling and pharmaceutical compositions thereof, and their use in therapeutic applications of those disorders.Type: ApplicationFiled: June 4, 2010Publication date: May 31, 2012Applicants: VIB VZW, Katholieke Universiteit Leuven, K.U. Leuven R&DInventors: Bart De Strooper, Amantha Thathiah
-
Publication number: 20110091446Abstract: The present invention relates to single domain antibodies with a specificity for BACE1. More specifically, the invention provides single variable domain antibodies derived from camelids which bind to BACE1 and are capable of inhibiting the activity of BACE1. Said antibodies can be used for research and medical applications. Specific applications include the use of BACE1 specific antibodies for the treatment of Alzheimer's disease.Type: ApplicationFiled: April 3, 2009Publication date: April 21, 2011Applicants: KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D, VRIJE UNIVERSITEIT BRUSSELInventors: Bart De Strooper, Els Marjaux, Lujia Zhou, Serge Muyldermans